Phenotypic Screening of Histone Deacetylase (HDAC) Inhibitors against Schistosoma mansoni.

Fiche publication

Date publication

août 2022

Journal

ChemMedChem

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ROMIER Christophe

Tous les auteurs :
Hassan MM, Sedighi A, Olaoye OO, Häberli C, Merz A, Ramos-Morales E, de Araujo ED, Romier C, Jung M, Keiser J, Gunning PT

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35983937

Résumé

Schistosomiasis is a prevalent yet neglected tropical parasitic disease caused by the Schistosoma genus of blood flukes. Praziquantel is the only currently available treatment, hence drug resistance poses a major threat. Recently, histone deacetylase 8 (HDAC8) selective inhibitors have been proposed as a viable treatment for schistosomiasis. Herein, we report the phenotypic screening of a focused library of small molecules of varying HDAC isozyme-inhibition profiles, including eight HDAC8 inhibitors with >10-fold selectivity in comparable functional inhibition assays and IC values against HDAC8<100 nM. HDAC8-selective inhibitors showed the lowest potency against Schistosoma mansoni newly transformed schistosomula (NTS). Pan-HDAC inhibitors MMH258, MMH259, and MMH373, as assessed by functional inhibition assays, with minimal or no-observed hHDAC8 and SmHDAC8 activities, were active against both NTS (MMH258, IC =1.5 μM; MMH259, IC =2.3 μM) and adult S. mansoni (MMH258, IC =2.1 μM; MMH373, IC =3.4 μM). Our results indicate that neither hHDAC8 nor SmHDAC8 activity were directly correlated to their NTS and adult S. mansoni activities.